首页> 外文会议>World congress of the International Photodynamic Association >Low Dose Photofrin? PDT for Recurrent In-Situ Squamous Cell Tumors of the Head and Neck
【24h】

Low Dose Photofrin? PDT for Recurrent In-Situ Squamous Cell Tumors of the Head and Neck

机译:低剂量Photofrin? PDT治疗头颈部复发性原位鳞状细胞瘤

获取原文

摘要

Multifocal recurrence of in-situ squamous cell cancer of the oral cavity, pharynx and vocal cord following surgical failure can be a therapeutic dilemma. Salvage surgery or radiation may be an option but morbidity can be significant. We evaluated the potential role of low dose Photofrin~? (1.2mg/Kg) Photodynamic Therapy for this cohort of patients.A total of 25 patients with multifocal recurrent in-situ squamous cell cancer of the oral cavity, pharynx and vocal cord who had failed local resection, and where additional surgery or radiation therapy would likely result in permanent morbidity, were offered Photodynamic Therapy. PDT consisted of off label infusion of Photofrin~? (1.2mg/kg) followed 48 hours later by illumination at 630nm employing a light diffuser (300J) and/or microlens (150Jcm~2).All patients completed their prescribed PDT and no patient has been lost to follow up (minimum 1 year). No photosensitivity reactions were noted. No significant morbidity was seen. All patients were able to maintain oral nutrition. Procedure related pain was well controlled by one week of oral narcotics. At one month post PDT all patients were biopsy negative in the treatment region and no failures within the treatment region have been noted. No fibrosis or permanent PDT morbidity has been seen with follow up to three years. Vocal cord and voice function were excellent.Three patients developed new regions of in-situ disease outside the PDT fields, two underwent additional PDT and one had laser resection.Low dose Photofrin~? PDT offers excellent palliation and durable local control of recurrent in-situ squamous cell cancers of the oral cavity, pharynx and true cords. This is a well tolerated therapy. Low dose Photofrin~? appears to improve selectivity and minimize normal tissue injury. It should be tested in a larger patient population.
机译:手术失败后口腔,咽和声带的原位鳞状细胞癌多灶复发可能是治疗上的难题。可以选择挽救手术或放疗,但发病率可能很高。我们评估了低剂量的Photofrin〜?的潜在作用。 (1.2mg / Kg)此人群的光动力疗法。 为总共25例局部切除失败且在其他手术或放疗可能导致永久性发病的地方多发性口腔,咽和声带多灶复发性原位鳞状细胞癌的患者提供了光动力疗法。 PDT由不合格的Photofrin〜?注入组成。 (1.2mg / kg),然后在48小时后,使用光扩散器(300J)和/或微透镜(150Jcm〜2)在630nm处进行照明。 所有患者均完成了规定的PDT,并且没有患者失去随访(至少1年)。没有观察到光敏反应。没有发现明显的发病率。所有患者均能够维持口腔营养。与手术相关的疼痛通过一周的口服麻醉药得到了很好的控制。 PDT后一个月,所有患者在治疗区域的活检均为阴性,并且未发现治疗区域内的失败。随访三年未见纤维化或PDT永久性发病。声带和语音功能非常出色。 三名患者在PDT领域以外出现了新的原位疾病区域,两名患者接受了另外的PDT,其中一名接受了激光切除。 低剂量的Photofrin〜? PDT可为口腔,咽部和真索的复发性原位鳞状细胞癌提供出色的缓解和持久的局部控制。这是一种耐受良好的疗法。低剂量的Photofrin〜?似乎可以提高选择性并最大程度地减少正常组织损伤。应该在更大的患者人群中进行测试。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号